"Chromans" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrans saturated in the 2 and 3 positions.
| Descriptor ID |
D002839
|
| MeSH Number(s) |
D03.383.663.283.240 D03.633.100.150.240
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chromans".
Below are MeSH descriptors whose meaning is more specific than "Chromans".
This graph shows the total number of publications written about "Chromans" by people in this website by year, and whether "Chromans" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chromans" by people in Profiles.
-
Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis. 2008 Jul; 199(1):207-14.
-
Management of the metabolic syndrome. Panminerva Med. 2005 Dec; 47(4):219-28.
-
Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes. 2005 Nov; 54(11):3319-25.
-
Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. J Clin Endocrinol Metab. 2005 Apr; 90(4):1986-91.
-
Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab. 2004 Jun; 89(6):2846-51.
-
Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care. 2004 Jun; 27(6):1365-8.
-
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002 Sep; 51(9):2796-803.
-
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes. 2000 May; 49(5):782-8.
-
TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials. 1998 Apr; 19(2):217-31.
-
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes. 1996 Nov; 45(11):1572-9.